Biocon Enhances Partnership with Mylan through Strategic

Bangalore, Karnataka, India, Thursday, February 14, 2013 -- (Business Wire
India) 
Biocon, Asia's premier biotechnology company today announced that it has entered
into a definitive agreement with Mylan for an exclusive strategic collaboration
for the global development and commercialization of generic versions of its
three insulin analog products.  
Biocon's Chairman & Managing Director, Kiran Mazumdar-Shaw said “Mylan is a
natural preferred partner for our portfolio of generic Insulin analogs and this
collaboration further strengthens our existing successful partnership. We are
excited to team up with Mylan to be able to cost effectively address the disease
and economic burden that diabetes poses to global health. We are confident that
together we can build a strong global presence in generic Insulin analogs and
thereby provide access to affordable therapy options to physicians, healthcare
providers and diabetes patients worldwide.” 
Mylan CEO Heather Bresch commented, “This collaboration builds off of our
existing successful partnership for generic biologics with Biocon and brings
Mylan a portfolio of high-value insulin analog products. This collaboration
further expands and diversifies our pipeline of complex,
difficult-to-manufacture products with strong future growth potential.
Importantly, we believe we have the opportunity to be one of the first generic
entrants in developed markets into the rapidly growing diabetes area, helping to
address unmet needs and reduce the economic burden to those battling the disease
and to the global healthcare system.”  
Mylan President Rajiv Malik added, “Biocon has served as a trusted development
partner for the past three years and we are very excited about this expanded
relationship. Our thorough review of the development work completed by Biocon to
date on these products gives us great confidence in the company's capabilities
in this area and in the quality and value of this program. Our confidence in the
potential of this program is supported by our proven ability to drive value from
our partnership with Biocon and we believe Mylan is uniquely positioned to work
with Biocon to bring these products to market.”  
Under the terms of this collaboration, Mylan will have the rights to develop and
market Biocon's Glargine (the generic version of Sanofi's Lantus®), Lispro (the
generic version of Eli Lilly's Humalog®) and Aspart (the generic version of
Novo Nordisk's NovoLog®).  
Mylan and Biocon will share development, capital and certain other costs to
bring the products to market. Mylan will have exclusive commercialization rights
in the U.S., Canada, Australia, New Zealand, the European Union and the European
Free Trade Association countries through a profit share arrangement with Biocon.
Mylan will have co-exclusive commercialization rights with Biocon in certain
other markets around the world.  
All other transaction terms remain confidential. 
According to public filings, reported worldwide net sales of Lantus, Humalog and
NovoLog for 2012 were approximately $11.5 billion. 
About Biocon Limited  
Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id:
INE376G01013) is India's largest biotechnology company by revenue. The Group,
promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven
healthcare enterprise with strategic focus on biopharmaceuticals and research
services. Biocon's value chain traverses the entire length of discovery,
development and commercialization of novel therapeutics. Biocon delivers
affordable solutions to partners and customers in over 75 countries across the
globe. Biocon's robust product offering includes the world's first Pichia-based
recombinant human Insulin, INSUGEN(R), Glargine, BASALOG® and India's first
indigenously produced monoclonal antibody BIOMAb-EGFR(TM) for head and neck
cancer. www.biocon.com. 
About Mylan Inc 
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit, do what's right, not what's easy and
impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately one-third of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 150 countries and
territories. Our workforce of more than 18,000 people is dedicated to improving
the customer experience and increasing pharmaceutical access to consumers around
the world. But don't take our word for it. See for yourself. See inside.
mylan.com. 
Disclaimer: This press release includes statements that constitute
"forward-looking statements“ including with regard to the collaboration and
commercialization of the products and the company's future opportunities. These
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Because such statements inherently
involve risks and uncertainties, actual future results may differ materially
from those expressed or implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, but are not limited to:
the content and timing of decisions by regulatory authorities related to the
development and commercialization of the products; difficulties or delays in
manufacturing; demand for and market acceptance for the products; the impact of
competitive products and pricing; and the other risks detailed in the company's
periodic filings with the Securities and Exchange Commission. The company
undertakes no obligation to update these statements for revisions or changes
after the date of this release. 
Media contact details 
Seema Ahuja, Head-Corporate Communications,
Biocon Limited,
+91 (80) 28082222/ +91 9972317792,
seema.ahuja@biocon.com 
Sweta Pachlangiya, Investor Relations,
Biocon Limited,
+91 (80) 28082045/ +91 9686509372,
sweta.pachlangiya@biocon.com 
Contributed via: Bloomberg Publisher WEB Service 
Provider ID: 8da46e316d8f48ca92e3cc1c83cad412 
-0- Feb/14/2013 05:18 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.